FDA.reportPublic FDA data

Vegzelma 100 MG in 4 ML Injection

RxCUI
2627656
RxNorm name
Vegzelma 100 MG in 4 ML Injection
Display name
Vegzelma 100 MG in 4 ML Injection
Full name
Vegzelma 100 MG in 4 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:57

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761268Vegzelmabevacizumab-adcd351(k) BiosimilarRx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VegzelmaBEVACIZUMAB-ADCDCELLTRION USA, Inc.4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe2025-05-08Warnings, Adverse reactionsExact identifier
rxcui: 2627656

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebeVegzelma 100 MG in 4 ML InjectionPSN4These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b20250508
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe4 ML Vegzelma 25 MG/ML InjectionSY4These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b20250508
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebeVegzelma 100 MG per 4 ML InjectionSY4These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b20250508
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe4 ML bevacizumab-adcd 25 MG/ML Injection [Vegzelma]SBD4These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b20250508